Literature DB >> 21349802

Restricted leptin antagonism as a therapeutic approach to treatment of autoimmune diseases.

Arash Babaei1, Sayyed Hamid Zarkesh-Esfahani, Ehsan Bahrami, Richard J Ross.   

Abstract

Leptin, the adipocyte derived hormone, has a pivotal role in regulating energy homeostasis and appetite. Beyond this essential role in bodyweight control, leptin also regulates the immune responses. Leptin has pro-inflammatory effects on T cell populations, shifting the T helper balance towards a TH1 phenotype, through induction of pro-inflammatory cytokines and stimulation of macrophage and natural killer cell function. Acute starvation reduces serum leptin levels, resulting in an impaired cellular immune response. The TH1 pro-inflammatory immune response, a homeostatic response mediated by the low leptin levels, is also impaired during starvation. Leptin-deficient or leptin receptor mutant mice are protected against the development of several inflammatory or various T cell-dependent autoimmune diseases. Therefore, leptin appears to have a central role in the immune response and low leptin levels may protect against autoimmune disease. Here we review the role of leptin in the immune responses, with emphasis on autoimmune diseases. We will also discuss the application of leptin antagonist therapy for prevention and treatment of immunity related disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21349802     DOI: 10.14310/horm.2002.1289

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN: 1109-3099            Impact factor:   2.885


  10 in total

Review 1.  Adipokine leptin in obesity-related pathology of breast cancer.

Authors:  Amitabha Ray
Journal:  J Biosci       Date:  2012-06       Impact factor: 1.826

Review 2.  Emerging role of leptin in rheumatoid arthritis.

Authors:  G Tian; J-N Liang; Z-Y Wang; D Zhou
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

3.  Ectopic endometrium-derived leptin produces estrogen-dependent chronic pain in a rat model of endometriosis.

Authors:  P Alvarez; O Bogen; X Chen; L C Giudice; J D Levine
Journal:  Neuroscience       Date:  2013-11-14       Impact factor: 3.590

4.  Leptin deficiency down-regulates IL-23 production in glomerular podocytes resulting in an attenuated immune response in nephrotoxic serum nephritis.

Authors:  Kei Goto; Yoshikatsu Kaneko; Yuya Sato; Tadashi Otsuka; Suguru Yamamoto; Shin Goto; Keiko Yamamoto; Tadashi Yamamoto; Hiroshi Kawachi; Michael P Madaio; Ichiei Narita
Journal:  Int Immunol       Date:  2015-11-13       Impact factor: 4.823

Review 5.  The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease.

Authors:  Udai P Singh; Narendra P Singh; Hongbing Guan; Brandon Busbee; Robert L Price; Dennis D Taub; Manoj K Mishra; Raja Fayad; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Int Rev Immunol       Date:  2013-07-10       Impact factor: 5.311

6.  SHORT CHAIN FATTY ACIDS UPREGULATE ADIPOKINE PRODUCTION IN TYPE 2 DIABETES-DERIVED HUMAN ADIPOCYTES.

Authors:  Y Naraoka; T Yamaguchi; A Hu; K Akimoto; H Kobayashi
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Jul-Sep       Impact factor: 0.877

7.  Leptin in pediatrics: A hormone from adipocyte that wheels several functions in children.

Authors:  Ashraf T Soliman; Mohamed Yasin; Ahmed Kassem
Journal:  Indian J Endocrinol Metab       Date:  2012-12

8.  Leptin and cancer: Pathogenesis and modulation.

Authors:  Deep Dutta; Sujoy Ghosh; Kaushik Pandit; Pradip Mukhopadhyay; Subhankar Chowdhury
Journal:  Indian J Endocrinol Metab       Date:  2012-12

Review 9.  Adipokines as drug targets in diabetes and underlying disturbances.

Authors:  Vinícius Andrade-Oliveira; Niels O S Câmara; Pedro M Moraes-Vieira
Journal:  J Diabetes Res       Date:  2015-04-08       Impact factor: 4.011

10.  Upregulation of Bone Morphogenetic Protein-2 Synthesis and Consequent Collagen II Expression in Leptin-stimulated Human Chondrocytes.

Authors:  Shun-Fu Chang; Rong-Ze Hsieh; Kuo-Chin Huang; Cheng Allen Chang; Fang-Yao Chiu; Hsing-Chun Kuo; Cheng-Nan Chen; Yu-Ping Su
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.